-
Celivarone is a noniodinated analog of amiodarone that is currently in clinical trials. This report gives us data about the effect of celivarone on ventricular arrhythmias in patients with implantable cardioverter-defibrillators (ICDs).
-
Recent clinical trials utilizing intravascular ultrasound (IVUS) to quantify coronary artery plaque burden have demonstrated that statin therapy has the potential to arrest the progression of coronary artery disease, and even to effect a small amount of plaque regression.
-
Dronedarone was approved by the FDA in the United States for the treatment of patients with atrial fibrillation (AF) several years ago.
-
-
A post-stroke analysis of more than 20,000 patients in 35 countries showed that the lowest risk systolic blood pressure (BP) range is 130-139 mmHg. There is a J-shaped curve of risk with an increase in recurrent stroke among patients with a systolic BP below 120 mmHg and above 140 mmHg.
-
The prevalence of Lyme meningitis among children with nonspecific aseptic meningitis occurring from April through December in the years 2006 through 2009 in an endemic area for Lyme disease was 13.3% (95% confidence interval [CI], 6.3%-25.1%).
-
Common specific causes of fever in Finnish returned travelers were Campylobacter, malaria, bacteremia, HIV, and influenza; they included a significant proportion of potentially life-threatening infections, and more than one diagnosis. Evaluation of such fevers should be systematic and thorough.
-
In this study of a statewide administrative database, among 138,720 adult patients admitted to an ICU, uninsured patients had a 25% higher likelihood of death within 30 days compared with privately insured patients, differences that persisted after multiple adjustments for demographics, severity of illness, and site of care. Uninsured patients received central venous catheterization, acute hemodialysis, and tracheostomy significantly less often than insured patients.
-
-
A post hoc analysis of patients with bacteremia due to ESBL-producing E.coli (ESBL-EC) from 6 published cohorts was performed. Treatment with B-lactam/B-lactamase inhibitors (BLBI) vs. carbapenems did not show any difference in mortality or length of hospital stay.